Stock Market & Financial Investment News

News Breaks November 27, 2012 06:43 EDT BSX Boston Scientific downgraded to Market Perform from Outperform at Bernstein Bernstein downgraded Boston Scientific citing continued share losses in its major cardiology business, lack of catalysts, and secular pressure in the drug eluting stent market. Price target remains $6. News For BSX From The Last 14 Days Check below for free stories on BSX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 16, 2013 16:13 EDT BSX Vascular Solutions files patent infringement complaint against Boston Scientific Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. 07:51 EDT BSX Boston Scientific price target raised to $12 from $9 at JMP Securities JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. 07:28 EDT BSX I/O Central to host a conference Subscribe for More Information May 14, 2013 15:33 EDT BSX Boston Scientific has a conference call hosted by JPMorgan JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. May 10, 2013 10:00 EDT BSX On The Fly: Analyst Upgrade Summary Subscribe for More Information 09:03 EDT BSX Boston Scientific receives CEO Mark approval for Rhythmia mapping system Subscribe for More Information 05:46 EDT BSX Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo Subscribe for More Information May 9, 2013 12:04 EDT BSX Boston Scientific says data show Watchman device superior to warfarin Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN Left Atrial Appendage Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization. The data demonstrated significant reductions in both cardiovascular and all death compared to warfarin. The data were presented today as a late-breaking clinical trial at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions. 09:27 EDT BSX Leerink's medical devices analyst holds a conference call Subscribe for More Information May 8, 2013 07:38 EDT BSX BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information May 6, 2013 08:06 EDT BSX Boston Scientific completes first-in-human clinical trial of IntellaTip Mifi XP Boston Scientific completed a first-in-human clinical trial utilizing the IntellaTip MiFi XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the United States. This single center feasibility trial enrolled 10 patients and was led by Prash Sanders, MBBS, PhD, FHRS, director of the Centre for Heart Rhythm Disorders at the University of Adelaide and the Royal Adelaide Hospital. Patients with type 1 atrial flutter may exhibit symptoms that include palpitations, shortness of breath, fatigue, lightheadedness and fainting. Catheter ablation, a procedure in which localized electrical energy is delivered into the heart tissue aimed at restoring the continuous normal rhythm, has become a first-line treatment approach for patients with recurrent type 1 atrial flutter and demonstrates more successful short- and long-term outcomes compared to anti-arrhythmic drug therapy. Sign up for a free trial to see the rest of the stories you've been missing.